Related articles - Bulevirtide:Application and safety
- Bulevirtide, a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta vir....
- Mar 29,2023
|
| Bulevirtide Basic information |
Product Name: | Bulevirtide | Synonyms: | Bulevirtide;Bulevirtide (Myrcludex B);MyrB;Propofol Impurity 48;{Myr}-Gly-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Asp-Phe-Asn-Pro-Asn-Lys-Asp-His-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly-NH2 | CAS: | 2012558-47-1 | MF: | | MW: | 0 | EINECS: | | Product Categories: | | Mol File: | Mol File | |
| Bulevirtide Chemical Properties |
form | Solid | color | White to off-white |
| Bulevirtide Usage And Synthesis |
Description |
Bulevirtide (BLV), the first-in-class entry inhibitor, is a 47-amino acid synthetic liner lipopeptide derived from the preS1 domain of the HBV large surface that targets the NTCP, the entry receptor for HBV/HDV. By blocking this receptor, new infections are prevented, and infected hepatocytes are replaced by naive cells that will be protected from infection. Consequently, viral spread in the liver is prevented.
| Biological Activity | The sequence of Bulevirtide (BLV) is derived from that of preS1 from HBV genotype C (residues Gly2-Gly48) with a shortening of the 11 additional N-terminal amino acids and one amino acid substitution, Gln46Lys. BLV exhibits a remarkably high inhibitory constant (IC50?=?140 pM) against HBV and HDV in primary human hepatocytes and HepaRG cells. BLV has also been demonstrated to inhibit the NTCP-mediated uptake of bile salts but at an IC50 in the nanomolar range[1]. | References |
[1] Liu, Hongtao et al. “Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.” Nature Communications 22 1 (2024).
|
| Bulevirtide Preparation Products And Raw materials |
|